tbuckley/cabot-search huggingface dataset:
Neoadjuvant chemoradiotherapy (NCRT) using concurrent S-1 and irinotecan in rectal cancer: Impact on long-term clinical outcomes and prognostic factors.
Authors: Atsuko Tsutsui, Takatoshi Nakamura, Keishi Yamashita, Takeo Sato, Masahiko Watanabe
Journal: Journal of Clinical Oncology (2013)

3556 Background: To assess long-term clinical outcomes of neoadjuvant chemoradiotherapy (NCRT) of rectal cancer using concurrent irinotecan and S-1. Methods: One hundred and fifteen patients without distant metastases entered this phase II trial in cT3/T4 rectal cancer (n=104/11). Pelvic radiotherapy was given to 45 Gy in 25 fractions over 5 weeks with concurrent oral S-1 at 80 mg/m 2 and intravenous irinotecan at 80 mg/m 2 once weekly. Median follow-up term was 60 months (ranged from 20 to 96 months). Results: Adverse effect of Grade 3 was recognized in 7 patients (6%), and completion rate of this NCRT regimen was 87 %. All 115 patients (100%) could undergo R0 surgical resection. Twenty-eight patients (24%) demonstrated a pathologic complete response (ypCR). Local recurrence-free survival was 93%, disease-free survival (DFS) was 79%, and overall survival (OS) was 80%. By the multivariate proportional hazard model for DFS and OS, ypN2 was only remnant independent prognostic factor (P=0.0019 and P=0.0064, respectively). ypN2 was recognized in 9 patients (8%), and prognosis was extremely dismal (8 patients were recurred within 2 years). We again performed the multivariate analysis for 106 cases restricted to ypN0/1, which exhibited 85% of DFS, and both ypT and tumor portion were independent predictors (P=0.0065 and P=0.003, respectively). Combination of them could greatly enrich high risk patients for recurrence (P&lt;0.0001), and dominant recurrences were uniquely found in lung. Conclusions: Novel NCRT regimen using S1/irinotecan demonstrated high response rates and excellent long-term survival, with acceptable adverse effects. ypN2 is a definitive indicator of dismal prognosis, and combination of ypT and tumor portion can identify high risk patients among the ypN0/1 patients.
Elective versus therapeutic neck dissection in the clinically node negative early oral cancer: A randomised control trial (RCT).
Authors: Anil D'Cruz, Mitali Dandekar, Richa Vaish, Supreeta Arya, Gouri Pantvaidya, Pankaj Chaturvedi, Devendra Chaukar, P. S. Pai, Anuja Deshmukh, Shubhada Kane, Deepa Nair, Sudhir Vasudevan Nair, Asawari Patil, Rohini W Hawaldar, Manasi Dhopeshwarkar, Jaiprakash Agarwal
Journal: Journal of Clinical Oncology (2015)

LBA3 Background: Management of the neck in early oral cancers has been a matter of debate with clinical equipoise between elective (END) or therapeutic neck dissection (TND). Methods: This is a prospective phase III RCT (NCT00193765) to test the superiority of END at the time of primary surgery over TND (neck dissection at the time of nodal relapse) in patients with lateralized T1 or T2 squamous carcinoma of oral cavity, amenable to peroral excision. Patients were stratified based on size, site, sex and preoperative neck ultrasound. The primary end point was overall survival (OS) and secondary end point was disease-free survival (DFS). The trial was planned to demonstrate a 10% superiority (1-sided α = 0.05 and β = 0.2) in OS for END vs. TND, assuming 60% 5-year OS in TND arm, with a planned sample size of 710. Results: This trial was terminated after 596 patients were randomized between January 2004 and June 2014. An interim intent-to-treat analysis of initial 500 patients (255 in TND, 245 END) with a minimum follow-up of 9 months was performed as mandated by Data and Safety Monitoring Committee based on the number of observed deaths in each arm. Both arms were balanced for site and stage. There were 427 tongue, 68 buccal mucosa and 5 floor of mouth tumors; 221 were TI and 279 T2. At a median follow-up of 39 months there were 146 recurrences in TND and 81 in END arms respectively. The 3-year OS was significantly higher in END compared to TND arm (80.0% vs. 67.5%, HR = 0.63, 95%CI 0.44-0.89, p = 0.01) as was 3-year DFS (69.5% vs. 45.9%, HR = 0.44, 95%CI 0.34-0.58, p &lt; 0.001). After adjusting for stratification factors in Cox regression, END continued to be significantly superior to TND for both OS and DFS. Conclusions: There were 8 excess deaths for every 15 excess recurrences in the TND arm. Elective neck dissection in patients with early oral SCC results in 37% reduction in mortality and should be considered the standard of care. Clinical trial information: NCT00193765.
K + Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria
Authors: Christina J. Groß, Ritu Mishra, Katharina S. Schneider, Guillaume Médard, Jennifer Wettmarshausen, Daniela C. Dittlein, Hexin Shi, Oliver Gorka, Paul-Albert Koenig, Stephan Fromm, Giovanni Magnani, Tamara Ćiković, Lara Hartjes, Joachim Smollich, Avril A.B. Robertson, Matthew A. Cooper, Marc Schmidt-Supprian, Michael Schuster, Kate Schroder, Petr Broz, Claudia Traidl-Hoffmann, Bruce Beutler, Bernhard Kuster, Jürgen Ruland, Sabine Schneider, Fabiana Perocchi, Olaf Groß
Journal: Immunity (2016)
Abstract 2010: A 54 year old Woman Presents with Angina, Syncope and a Devastating Clinical Course
Authors: Neal Lakdawala, James Fang
Journal: Circulation (2006)

A 54 year-old woman presented with a 2 week history of exertional chest discomfort and recent syncope. She described the discomfort as substernal chest pressure often accompanied by dyspnea. She ha...
Co-Culture of CLL Cells with MEACs (Myosin Heavy Chain IIA Exposed Apoptotic Cells) Promotes Viability of Leukemic Clones
Authors: Charles C. Chu, Xiaoxuan Cui, Rosa Catera, Lu Zhang, Amanda R. Magli, Xiao-Jie Yan, Jonathan E. Kolitz, Steven L. Allen, Kanti R. Rai, Nicholas Chiorazzi
Journal: Blood (2011)
Dysphagia due to kyphosis-induced positional changes of the carotid artery
Authors: Koichi Tsunoda, Takeshi Wakabayashi, Junzo Takeda
Journal: Endoscopy (2016)

We have recently encountered numerous patients with age-related aberrations of the carotid artery [1] [2] [3] [4]. This pathological condition is also a suspected risk factor for ischemic stroke [2] [3] [4] and has not been identified during previous physical examinations [3] [4].
Human vascular progenitor cells derived from renal arteries are endothelial-like and assist in the repair of injured renal capillary networks
Authors: Paul Pang, Molly Abbott, Steven L. Chang, Malyun Abdi, Nikita Chauhan, Murti Mistri, Joshua Ghofrani, Quynh-Anh Fucci, Colleen Walker, Corey Leonardi, Samuel Grady, Arvin Halim, Ryan Hoffman, Tzongshi Lu, Huixia Cao, Stefan G. Tullius, Sayeed Malek, Sanjaya Kumar, Graeme Steele, Adam Kibel, Benjamin S. Freedman, Sushrut S. Waikar, Andrew M. Siedlecki
Journal: Kidney International (2016)
DNA Methylation Independent Silencing of the RARα Gene Expression in Acute Myeloid Leukemia.
Authors: Annegret Glasow, Angela Barrett, Manuel Boix Chornet, Rajeev Gupta, Da-cheng Zhou, Robert Gallagher, Marieke von Lindern, Samuel Waxman, Tariq Enver, Guido Hildebrandt, Arthur Zelent
Journal: Blood (2006)
The Lymphatic System: Integral Roles in Immunity
Authors: Gwendalyn J. Randolph, Stoyan Ivanov, Bernd H. Zinselmeyer, Joshua P. Scallan
Journal: Annual Review of Immunology (2016)

The lymphatic vasculature is not considered a formal part of the immune system, but it is critical to immunity. One of its major roles is in the coordination of the trafficking of antigen and immune cells. However, other roles in immunity are emerging. Lymphatic endothelial cells, for example, directly present antigen or express factors that greatly influence the local environment. We cover these topics herein and discuss how other properties of the lymphatic vasculature, such as mechanisms of lymphatic contraction (which immunologists traditionally do not take into account), are nonetheless integral in the immune system. Much is yet unknown, and this nascent subject is ripe for exploration. We argue that to consider the impact of lymphatic biology in any given immunological interaction is a key step toward integrating immunology with organ physiology and ultimately many complex pathologies.
Genome Editing of Monogenic Neuromuscular Diseases
Authors: Chengzu Long, Leonela Amoasii, Rhonda Bassel-Duby, Eric N. Olson
Journal: JAMA Neurology (2016)

<h3>Importance</h3> Muscle weakness, the most common symptom of neuromuscular disease, may result from muscle dysfunction or may be caused indirectly by neuronal and neuromuscular junction abnormalities. To date, more than 780 monogenic neuromuscular diseases, linked to 417 different genes, have been identified in humans. Genome-editing methods, especially the CRISPR (clustered regularly interspaced short palindromic repeats)–Cas9 (CRISPR-associated protein 9) system, hold clinical potential for curing many monogenic disorders, including neuromuscular diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, amyotrophic lateral sclerosis, and myotonic dystrophy type 1. <h3>Objectives</h3> To provide an overview of genome-editing approaches; to summarize published reports on the feasibility, efficacy, and safety of current genome-editing methods as they relate to the potential correction of monogenic neuromuscular diseases; and to highlight scientific and clinical opportunities and obstacles toward permanent correction of disease-causing mutations responsible for monogenic neuromuscular diseases by genome editing. <h3>Evidence Review</h3> PubMed and Google Scholar were searched for articles published from June 30, 1989, through June 9, 2016, using the following keywords:<i>genome editing</i>,<i>CRISPR-Cas9</i>,<i>neuromuscular disease</i>,<i>Duchenne muscular dystrophy</i>,<i>spinal muscular atrophy</i>,<i>amyotrophic lateral sclerosis,</i>and<i>myotonic dystrophy type 1</i>. The following sources were reviewed: 341 articles describing different approaches to edit mammalian genomes; 330 articles describing CRISPR-Cas9–mediated genome editing in cell culture lines (in vitro) and animal models (in vivo); 16 websites used to generate single-guide RNA; 4 websites for off-target effects; and 382 articles describing viral and nonviral delivery systems. Articles describing neuromuscular diseases, including Duchenne muscular dystrophy, spinal muscular atrophy, amyotrophic lateral sclerosis, and myotonic dystrophy type 1, were also reviewed. <h3>Findings</h3> Multiple proof-of-concept studies reveal the feasibility and efficacy of genome-editing–meditated correction of monogenic neuromuscular diseases in cultured cells and animal models. <h3>Conclusions and Relevance</h3> Genome editing is a rapidly evolving technology with enormous translational potential once efficacy, delivery, and safety issues are addressed. The clinical impact of this technology is that genome editing can permanently correct disease-causing mutations and circumvent the hurdles of traditional gene- and cell-based therapies.
P0098 : Macrophage inhibitory cytokine-1 (MIC-1) is associated with degree of liver fibrosis in HCV-related liver disease - The MILC Study
Authors: B. Watson, A. Baxter, V. Flood, L. Schofield, H.P. Zhang, M. Lee-Ng, D. How-Chow, S.N. Breit, D.A. Brown, M. Danta
Journal: Journal of Hepatology (2015)
Memory B Cells of Mice and Humans
Authors: Florian Weisel, Mark Shlomchik
Journal: Annual Review of Immunology (2017)

We comprehensively review memory B cells (MBCs), covering the definition of MBCs and their identities and subsets, how MBCs are generated, where they are localized, how they are maintained, and how they are reactivated. Whereas naive B cells adopt multiple fates upon stimulation, MBCs are more restricted in their responses. Evolving work reveals that the MBC compartment in mice and humans consists of distinct subpopulations with differing effector functions. We discuss the various approaches to define subsets and subset-specific roles. A major theme is the need to both deliver faster effector function upon reexposure and readapt to antigenically variant pathogens while avoiding burnout, which would be the result if all MBCs generated only terminal effector function. We discuss cell-intrinsic differences in gene expression and signaling that underlie differences in function between MBCs and naive B cells and among MBC subsets and how this leads to memory responses.
MODERN POST-OPERATIVE RADIOTHERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER MAY IMPROVE LOCAL CONTROL AND SURVIVAL: A PUBLICATION-BASED META-ANALYSIS
Authors: Charlotte Billiet, Herbert Decaluwe, Stéphanie Peeters, Johan Vansteenkiste, Christophe Dooms, Paul De Leyn, Dirk De Ruysscher
Journal: Journal of Thoracic Oncology (2013)
Carboplatin plus paclitaxel as first-line therapy for locally advanced recurrent metastatic endometrial cancer.
Authors: H. Attarian, H. Rezvani, M. Ghadyani, A. Okhovatian, A. Khosravi, S. Attarian
Journal: Journal of Clinical Oncology (2010)

e15553 Background: To evaluate the efficacy and safety of carboplatin plus paclitaxel in patients with advanced loco regional, recurrent and metastatic endometrial cancer. Methods: Thirty two eligible patients (median age 62, range 41-72) with measurable endometrial cancer were treated with carboplatin (AUC = 6) and paclitaxel (175 mg/m3) every 4 weeks for 6 cycles or until disease progression or severe toxicity. Results: The overall response rate was 54% (16 out of 30), complete remission (CR) in 4 and partial remission (PR) in 12. The median progression free survival was 8.2 months. Six months overall survival was seen in 80%. Toxicity was generally tolerated. Conclusions: The combination of carboplatin plus paclitaxel was well tolerated in this trial. This regimen demonstrated feasible activity in advanced endometrial cancer compared to other combination therapies used before, in terms of response rate and toxicity. No significant financial relationships to disclose.
BLIMP1 Is Commonly Inactivated In Anaplastic Large T-Cell Lymphomas (ALCL)
Authors: Michela Boi, Andrea Rinaldi, Roberto Piva, Paola MV Rancoita, Paola Bonetti, Andras Matolcsy, Thomas Tousseyn, Socorro Maria Rodríguez-Pinilla, Miguel Piris, Sílvia Beà, Elias Campo, Govind Bhagat, Steven H. Swerdlow, Andreas Rosenwald, Maurilio Ponzoni, Ken H. Young, Pier Paolo Piccaluga, Stefano Pileri, Antonino Neri, Enzo Medico, Emanuele Zucca, Ivo Kwee, Giorgio Inghirami, Francesco Bertoni
Journal: Blood (2011)
Multifunctional WS<sub>2</sub>@Poly(ethylene imine) Nanoplatforms for Imaging Guided Gene‐Photothermal Synergistic Therapy of Cancer
Authors: Chunfang Zhang, Yuan Yong, Li Song, Xinghua Dong, Xiao Zhang, Xiangfeng Liu, Zhanjun Gu, Yuliang Zhao, Zhongbo Hu
Journal: Advanced Healthcare Materials (2016)

The combination of photothermal therapy (PTT) with gene therapy (GT) to improve PTT efficiency and thus eliminate cancer cells under mild hyperthermia is highly needed. Herein, multifunctional WS2 @poly(ethylene imine) (WS2 @PEI) nanoplatform has been designed and constructed for gene-photothermal synergistic therapy of tumors at mild condition. After a surface modification of WS2 with a positively charged PEI, the as-prepared WS2 @PEI nanoplatform can not only act as an efficient survivin-siRNA carrier for GT but also exhibit remarkable near-infrared (NIR) photothermal effects for PTT. On the one hand, the photothermal effects induced by WS2 @PEI upon NIR irradiation can enhance the cellular uptake owing to the increase of the cell membrane permeability, which leads to the remarkable enhancement of silencing efficiency of survivin. On the other hand, the silencing of survivin can increase the apoptosis as well as reduce the heat resistance of cancer cells by downregulating the heat shock protein 70 expressions, which greatly enhance the sensitivity of cancer cells to PTT. As a result, compared to PTT or GT treatment alone, WS2 @PEI mediated synergistic GT/PTT therapy remarkably enhances in vitro cancer cell damage and in vivo tumor elimination.
Concomitant mutation and amplification of the ERBB2 (HER2) gene in human tumors.
Authors: Tobias Grob, Mareike Sandmann, Alexander Quaas, Andreas Marx, Guido Sauter
Journal: Journal of Clinical Oncology (2014)

11071 Background: Amplification of the ERBB2 (HER2) gene is a well-known genetic aberration in many tumor entities. Up to 20% of breast and gastric cancer show ERBB2 gene amplification and anti-HER2 targeting therapies are well established for these tumors. In other tumor entities such as lung cancer, colorectal cancer and bladder cancer the fraction of ERBB2 amplified tumors is considerably lower. In contrast to breast cancer, these tumors show heterogeneity of ERBB2 amplification in a substantial proportion. Oncogenic EGFR mutation with subsequent EGFR amplification is a common phenomenon in lung cancer. In analogy, primary ERBB2 mutation could explain the observed heterogeneity of ERBB2 amplification in some tumors. Methods: 100 tumors showing ERBB2 amplification by fluorescence in situ hybridization were examined for ERBB2 mutation: 50 breast cancer samples, including 10 cases with borderline gene amplification, 10 cases with heterogeneous gene amplification and 11 samples of metastatic lesions as well as 15 colorectal carcinomas, 12 gastric carcinomas, 12 non-small cell lung cancers and 10 urothelial carcinomas. Tumor DNA was extracted and examined for mutations in the tyrosine kinase domain (exons 18-23) of the ERBB2 gene by Sanger sequencing. Results: ERBB2 mutation was found in two metastatic lesions of breast cancer, two lung cancers and two colorectal cancers. In five of these cases short in-frame insertions in exon 20 were found. In one case of a breast cancer lung metastasis a missense mutation in exon 19 (p.L755S) was detected. The semi-quantitative chromatograms show an overrepresentation of the mutations indicating a selective amplification of the mutated allele. Conclusions: In certain tumor entities the heterogeneity of ERBB2 amplification indicates a late genetic event. The finding of a concomitant mutation in ERBB2 amplified tumors might explain the heterogeneity in some of these tumors. The effect of a primary oncogenic ERBB2 mutation might be increased by selective amplification of the mutated allele resulting in an additional growth advantage. If ERBB2 amplified tumors with a primary ERBB2 mutation also benefit from an HER2 targeted therapy needs to be elucidated.
Obstructive sleep apnoea and bone health
Authors: Claudio Liguori, Eleonora Piccirilli, Francesca Izzi, Nicola Biagio Mercuri, Umberto Tarantino, Fabio Placidi
Journal: European Respiratory Journal (2016)

We thank J-Y. Zhong and L-Q. Yuan for their comments on our paper investigating bone mineral density (BMD) in male obstructive sleep apnoea (OSA) patients [1]. In our report, published in the European Respiratory Journal [1], we documented that male patients with severe OSA (apnoea–hypopnoea index >30 events·h−1) show a severely decreased BMD in the lumbar spine and femur compared with male controls matched for age, body mass index and physical activity. We also documented that OSA patients present an increased risk for osteopenia and osteoporosis. In keeping with our findings, Chi-squared analysis corrected for continuity showed that T-scores consistent with osteopenia/osteoporosis were more frequent in OSA patients compared with controls at all regions of the lumbar spine and at the femur neck, upper femur neck and Ward triangle [1]. Obstructive sleep apnoea represents a risk factor for osteopenia and osteoporosis in male patients at all ages <http://ow.ly/c9Tn302PPKz>
<i>Sunset on the Sea</i>
Authors: Carrie A. Butt
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Investigating Teamwork in the Operating Room
Authors: Lane L. Frasier, Sudha R. Pavuluri Quamme, Aimee Becker, Sara Booth, Adam Gutt, Douglas Wiegmann, Caprice C. Greenberg
Journal: JAMA Surgery (2016)

This exploratory qualitative study engaged stakeholders as part of an attempt to design and implement best practice guidelines or team training interventions to enhance communication and teamwork in the operating room.
Expression of PRAME and MAGE-A3 in Asian and European patients with non-small cell lung cancer (NSCLC), bladder cancer, or hepatocellular carcinoma (HCC).
Authors: Patrick Therasse, Albert Linder, Sumitra Thongprasert, Pan-Chyr Yang, Po-Huang Lee, Tawesak Tanwandee, Jin Hyoung Kang, Jungsin Lee, Kesavan Sittampalam, Anon Chotirosniramit, Ross A. Soo, Hendrik Van Poppel, Evelyne Lerut, Steven Joniau, Thierry Coche, Olivier Gruselle, Diego D'Agostino, Aung Myo, Jamila Louahed
Journal: Journal of Clinical Oncology (2012)

e13061 Background: Antigen (Ag)-specific cancer immunotherapy is based on induction of immune responses (humoral and cell-mediated) specifically targeting Ags expressed by tumor cells. This may be achieved by delivering the Ag as a recombinant protein combined with potent immunostimulants. PRAME and MAGE-A3 are tumor Ags with distinct tumor expression patterns, both under investigation as targets for immunotherapy in NSCLC and malignant melanoma. For additional clinical development of these immunotherapies in other cancer types, expression of PRAME and MAGE-A3 in these cancers must be investigated taking into account patient ethnicity and tumor characteristics. Methods: 4 retrospective studies were performed, each including all tumor stages: NSCLC pts (in Asia and Europe); bladder cancer pts in Europe; HCC pts in Asia. Formalin-fixed paraffin embedded tumor tissues were tested for PRAME and MAGE-A3 expression by quantitative RT-PCR using an expression cut-off value for positivity. Exploratory analyses of possible associations with patient and tumor characteristics were done to identify factors that may impact Ag expression. Results: The overall Ag expression rates are shown in the table below. In NSCLC, both Ags were expressed less frequently in Asian than in European patients (the histological distribution was the same). NSCLC tumors more frequently expressed PRAME than MAGE-A3 while the reverse tendency was seen for bladder tumors and HCC. In the NSCLC studies, squamous cell carcinomas expressed both Ags more frequently than adenocarcinomas. No study found any association between tumor stage and Ag expression. Some 60% of the tumors express at least one of the Ags. Conclusions: The expression rates of PRAME and MAGE-A3 are sufficiently high to consider these Ags as targets for immunotherapy against NSCLC, bladder cancer and HCC. [Table: see text]